# Davita Inc.: overview

DVA · NYSE · CIK 927066 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dva.md) · [Financials](/companies/dva/financials.md) · [Filings](/companies/dva/filings.md) · [Insiders](/companies/dva/insiders.md)

Latest reported revenue: [$3.58bn](/filings/0000927066-26-000134.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:Revenues, accession 0000927066-26-000134).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,295 d](/filings/0000927066-26-000012.md) | [3,224](/filings/0000927066-26-000062.md) | [3,380](/filings/0000927066-26-000108.md) | [3,420](/filings/0000927066-26-000134.md) | [3,620 d](/filings/0000927066-26-000012.md) | [3,416](/filings/0000927066-26-000062.md) | [3,554](/filings/0000927066-26-000108.md) | [3,578](/filings/0000927066-26-000134.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [17.2% d](/filings/0000927066-26-000012.md) | [13.6%](/filings/0000927066-26-000062.md) | [15.9%](/filings/0000927066-26-000108.md) | [14.8%](/filings/0000927066-26-000134.md) | [15.5% d](/filings/0000927066-26-000012.md) | [14.1%](/filings/0000927066-26-000062.md) | [16.3%](/filings/0000927066-26-000108.md) | [14.0%](/filings/0000927066-26-000134.md) |
| Net margin | % | [7.9% d](/filings/0000927066-26-000012.md) | [5.1%](/filings/0000927066-26-000062.md) | [5.9%](/filings/0000927066-26-000108.md) | [4.4%](/filings/0000927066-26-000134.md) | [6.5% d](/filings/0000927066-26-000012.md) | [5.8%](/filings/0000927066-26-000062.md) | [7.5%](/filings/0000927066-26-000108.md) | [6.2%](/filings/0000927066-26-000134.md) |
| Diluted EPS | $ per share | not reported | [2.00](/filings/0000927066-26-000062.md) | [2.58](/filings/0000927066-26-000108.md) | [2.04](/filings/0000927066-26-000134.md) | not reported | [2.87](/filings/0000927066-26-000062.md) | [4.02](/filings/0000927066-26-000108.md) | [3.40](/filings/0000927066-26-000134.md) |
| Free cash flow | $m | [377 d](/filings/0000927066-26-000012.md) | [36.8](/filings/0000927066-26-000062.md) | [203 d](/filings/0000927066-26-000108.md) | [675 d](/filings/0000927066-26-000134.md) | [395 d](/filings/0000927066-26-000012.md) | [219](/filings/0000927066-26-000062.md) | [320 d](/filings/0000927066-26-000108.md) | [359 d](/filings/0000927066-26-000134.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [11.6](/filings/0000927066-24-000013.md) | [11.6](/filings/0000927066-25-000012.md) | [12.1](/filings/0000927066-26-000012.md) | [12.8](/filings/0000927066-26-000012.md) | [13.6](/filings/0000927066-26-000012.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [15.5%](/filings/0000927066-24-000013.md) | [11.5%](/filings/0000927066-25-000012.md) | [13.2%](/filings/0000927066-26-000012.md) | [16.3%](/filings/0000927066-26-000012.md) | [15.0%](/filings/0000927066-26-000012.md) |
| Net margin | % | [8.4%](/filings/0000927066-24-000013.md) | [4.8%](/filings/0000927066-25-000012.md) | [5.7%](/filings/0000927066-26-000012.md) | [7.3%](/filings/0000927066-26-000012.md) | [5.5%](/filings/0000927066-26-000012.md) |
| Diluted EPS | $ per share | [8.90](/filings/0000927066-24-000013.md) | [5.85](/filings/0000927066-25-000012.md) | [7.42](/filings/0000927066-26-000012.md) | [10.73](/filings/0000927066-26-000012.md) | [9.84](/filings/0000927066-26-000012.md) |
| Free cash flow | $bn | [1.3](/filings/0000927066-24-000013.md) | [1.0](/filings/0000927066-25-000012.md) | [1.5](/filings/0000927066-26-000012.md) | [1.5](/filings/0000927066-26-000012.md) | [1.3](/filings/0000927066-26-000012.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dva/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-27 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 382,563 | $180.4305 | $69.0m | [Form 4](/filings/0001193125-26-438090.md) |
| 2026-07-31 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 182,980 | $199.548 | $36.5m | [Form 4](/filings/0001193125-26-333151.md) |
| 2026-05-01 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 1,220,376 | $149.8429 | $182.9m | [Form 4](/filings/0001193125-26-207021.md) |
| 2026-01-29 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 1,658,480 | $120.5561 | $199.9m | [Form 4](/filings/0001193125-26-033900.md) |
| 2025-10-27 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 401,514 | $135.3558 | $54.3m | [Form 4](/filings/0001193125-25-256858.md) |
| 2025-07-31 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 1,635,962 | $140.6052 | $230.0m | [Form 4](/filings/0000950170-25-102306.md) |
| 2025-05-27 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 11,978 | $140.1794 | $1.7m | [Form 4](/filings/0000950170-25-078056.md) |
| 2025-05-27 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 71,966 | $139.5581 | $10.0m | [Form 4](/filings/0000950170-25-078056.md) |
| 2025-05-27 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 19,330 | $138.5916 | $2.7m | [Form 4](/filings/0000950170-25-078056.md) |
| 2025-05-23 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 800 | $138.60 | $110.9k | [Form 4](/filings/0000950170-25-078056.md) |
| 2025-05-23 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 36,094 | $138.1933 | $5.0m | [Form 4](/filings/0000950170-25-078056.md) |
| 2025-05-23 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 27,172 | $137.2775 | $3.7m | [Form 4](/filings/0000950170-25-078056.md) |
| 2025-05-22 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 1,256 | $139.8798 | $175.7k | [Form 4](/filings/0000950170-25-078056.md) |
| 2025-05-22 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 31,404 | $138.9407 | $4.4m | [Form 4](/filings/0000950170-25-078056.md) |
| 2025-05-08 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 1,145,938 | $147.108 | $168.6m | [Form 4](/filings/0000950170-25-069150.md) |
| 2025-02-19 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 9,477 | $155.2467 | $1.5m | [Form 4](/filings/0000950170-25-023556.md) |
| 2025-02-19 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 54,979 | $154.475 | $8.5m | [Form 4](/filings/0000950170-25-023556.md) |
| 2025-02-19 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 65,482 | $153.605 | $10.1m | [Form 4](/filings/0000950170-25-023556.md) |
| 2025-02-18 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 1,800 | $158.01 | $284.4k | [Form 4](/filings/0000950170-25-023556.md) |
| 2025-02-18 | [Berkshire Hathaway Inc](/insiders/1067983.md) | 10% owner | Sale (S) | 200 | $156.11 | $31.2k | [Form 4](/filings/0000950170-25-023556.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Berkshire Hathaway Inc](/funds/1067983.md) | 2026-06-30 | $6.43bn | 28,880,209 |  | Reduced −1,220,376 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $547.5m | 2,460,987 |  | Reduced −305,764 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $467.5m | 2,101,425 |  | Reduced −78,800 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $356.3m | 1,601,710 |  | Reduced −64,328 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $306.6m | 1,377,914 |  | Reduced −101,686 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $294.3m | 1,323,019 |  | Reduced −28,718 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $269.6m | 1,211,917 |  | Reduced −255,964 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $253.1m | 1,137,814 |  | Reduced −7,622 |
| [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $205.8m | 925,579 |  | Added +393,492 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $197.8m | 889,082 |  | Reduced −221,069 |

## Recent filings

[All 2,219 filings](/companies/dva/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 17:03 ET | [10-Q](/filings/0000927066-26-000134.md) | Quarterly report, period 2026-09-30 | 0000927066-26-000134 |
| 2026-10-29 | 16:06 ET | [8-K](/filings/0000927066-26-000132.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000927066-26-000132 |
| 2026-08-04 | 17:03 ET | [10-Q](/filings/0000927066-26-000108.md) | Quarterly report, period 2026-06-30 | 0000927066-26-000108 |
| 2026-08-04 | 16:08 ET | [8-K](/filings/0000927066-26-000105.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000927066-26-000105 |
| 2026-06-08 | 16:33 ET | [8-K](/filings/0001206774-26-000316.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001206774-26-000316 |
| 2026-05-05 | 17:03 ET | [10-Q](/filings/0000927066-26-000062.md) | Quarterly report, period 2026-03-31 | 0000927066-26-000062 |
| 2026-05-05 | 16:09 ET | [8-K](/filings/0000927066-26-000060.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000927066-26-000060 |
| 2026-04-22 | 16:30 ET | [DEF 14A](/filings/0000927066-26-000053.md) | Proxy statement, period 2025-12-31 | 0000927066-26-000053 |
| 2026-02-11 | 16:06 ET | [10-K](/filings/0000927066-26-000012.md) | Annual report, period 2025-12-31 | 0000927066-26-000012 |
| 2026-02-02 | 16:07 ET | [8-K](/filings/0000927066-26-000004.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000927066-26-000004 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000927066-26-000012.md), filed Feb 11, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/09557d4d-ab72-4a32-a0b8-fc9b95035541)

## About the filer

- CIK: 927066
- Tickers: DVA
- Exchange: NYSE
- SIC code: 8090 Services-Misc Health & Allied Services, NEC
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 20:16 ET. No prices; not investment advice.